| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 4,980 | 5,650 | 0 |
| Sales Growth | unch | -100.00% | -11.86% | unch | unch |
| Net Income | -6,260 | -13,420 | -18,640 | -17,900 | 0 |
| Net Income Growth | +53.35% | +28.00% | -4.13% | unch | +100.00% |
Qualigen Therapeutics Inc (QLGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Qualigen Therapeutics Inc. is a biotechnology company. It is focused on developing products for the treatment and testing of cancer and infectious diseases. The company's product pipeline consist AS1411 and Gold Nanoparticle ALAN, RAS-F3 and STARS(TM) blood cleansing system, which are in clinical stage. Qualigen Therapeutics Inc., formerly known as Ritter Pharmaceuticals Inc., is based in CA, United States.
Fiscal Year End Date: 12/31